GLP-1 Drugs Cause Weight Loss but 20-30% Comes From Muscle — What Does This Mean? | Research

The takeaway

GLP-1 receptor agonists primarily reduce fat (including dangerous visceral fat), but 20-30% of total weight loss consists of lean mass, raising concerns about muscle loss that may increase frailty risk.

20-30% lean mass loss
Proportion of total weight loss from GLP-1 receptor agonist therapy that consists of lean tissue rather than fat — raising questions about muscle preservation and long-term functional consequences

What the researchers found

GLP-1-based therapies predominantly reduce adipose tissue, including visceral and ectopic fat depots, but they also produce absolute reductions in lean mass representing 20-30% of total weight loss. This ratio is generally consistent with the lean-to-fat loss ratio seen with other forms of weight loss.

The review highlights sarcopenia (age-related muscle loss) and sarcopenic obesity as conditions of particular concern, given their overlap with the populations being treated with GLP-1 drugs. Data on dual and triple agonists (tirzepatide, retatrutide) are emerging but remain limited. The extent to which lean mass reduction translates into impaired muscle function or increased frailty vulnerability remains unclear.

Why it matters

Millions of people are using GLP-1 receptor agonists for weight loss, and many will lose significant amounts of lean tissue along with fat. For older adults, those with limited mobility, or patients who are already losing muscle with age, this lean mass loss could increase fall risk, reduce independence, and accelerate frailty. Understanding and mitigating this risk is essential for safe long-term use of these peptide drugs.

How the study worked

This is a narrative review integrating physiological, clinical, and mechanistic perspectives from preclinical studies and randomized clinical trials. It covers the physiology of incretin hormones, their potential relevance to muscle health, body composition changes during GLP-1 therapy, and the clinical implications of lean mass loss.

What this study cannot tell us

Current studies are constrained by methodological heterogeneity in body composition measurement, small sample sizes, and limited assessment of functional outcomes (strength, physical performance). Most trials report total lean mass changes without differentiating skeletal muscle from other lean tissue. Data on dual and triple agonists are still very limited. The review does not include a systematic search or meta-analysis.

How to read the evidence

This is a narrative review synthesizing evidence from multiple preclinical studies and randomized clinical trials. While it provides a comprehensive overview, the underlying evidence base is limited by methodological variability, small sample sizes, and insufficient functional outcome assessment.

When this study was published

Published in 2025, this review addresses one of the most pressing current questions in GLP-1 therapy as these peptide drugs see unprecedented adoption rates globally.

The bigger picture

This review addresses one of the most important open questions about the GLP-1 receptor agonist revolution: what happens to body composition, not just body weight? As these peptide drugs become some of the most prescribed medications globally, the muscle mass question has significant public health implications. The answer will shape how clinicians prescribe these drugs and what complementary interventions they recommend.

Questions still open

Does resistance training during GLP-1 therapy preserve lean mass without compromising fat loss?
Are certain GLP-1 receptor agonists better than others at preserving muscle during weight loss?
Should GLP-1 therapy include mandatory muscle function monitoring and exercise prescriptions, especially for older patients?

Common questions

Will I lose muscle on semaglutide or tirzepatide?

Research shows that 20-30% of the weight you lose on GLP-1 drugs comes from lean tissue (which includes muscle). This is similar to the muscle loss ratio seen with other weight loss methods. The remaining 70-80% comes from fat. To minimize muscle loss, experts recommend resistance training and adequate protein intake while on these medications.

Is the muscle loss from GLP-1 drugs dangerous?

It's not yet clear whether the lean mass loss from GLP-1 therapies meaningfully impairs muscle strength or physical function. For younger, active adults the impact may be minimal, but for older adults or those already losing muscle with age, it could increase risk of falls and frailty. This is an active area of research, and guidelines are still evolving.

Read the original research

The Influence of Glucagon-like Peptide-1 Receptor Agonists and Other Incretin Hormone Agonists on Body Composition.

International journal of molecular sciences, 26(24)

View on PubMed ↗Publisher’s paper ↗

Citation

Chrysavgis, Lampros; Mourelatou, Niki Gerasimoula; Koloutsou, Maria-Evangelia; Rozani, Sophia; Cholongitas, Evangelos. (2025). The Influence of Glucagon-like Peptide-1 Receptor Agonists and Other Incretin Hormone Agonists on Body Composition.. International journal of molecular sciences, 26(24). https://doi.org/10.3390/ijms262412130